285 related articles for article (PubMed ID: 21142808)
1. Investigational antibody-drug conjugates for hematological malignancies.
Polson AG; Ho WY; Ramakrishnan V
Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
3. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates: targeted drug delivery for cancer.
Alley SC; Okeley NM; Senter PD
Curr Opin Chem Biol; 2010 Aug; 14(4):529-37. PubMed ID: 20643572
[TBL] [Abstract][Full Text] [Related]
5. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
6. ATPase inhibitors of heat-shock protein 90, second season.
Janin YL
Drug Discov Today; 2010 May; 15(9-10):342-53. PubMed ID: 20230904
[TBL] [Abstract][Full Text] [Related]
7. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
Rossi C; Chrétien ML; Casasnovas RO
Target Oncol; 2018 Jun; 13(3):287-308. PubMed ID: 29556925
[TBL] [Abstract][Full Text] [Related]
9. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
10. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates for cancer: poised to deliver?
Hughes B
Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367
[No Abstract] [Full Text] [Related]
12. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
Blumel S; Goodrich A; Martin C; Dang NH
Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
[TBL] [Abstract][Full Text] [Related]
14. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
15. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
16. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
Prowell T
Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
[No Abstract] [Full Text] [Related]
17. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
18. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi).
Sacchi S; Russo D; Avvisati G; Dastoli G; Lazzarino M; Pelicci PG; Bonora MR; Visani G; Grassi C; Iacona I; Luzzi L; Vanzanelli P
Haematologica; 1997; 82(1):106-21. PubMed ID: 9107096
[TBL] [Abstract][Full Text] [Related]
19. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
20. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates.
Gromek SM; Balunas MJ
Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
